Literature DB >> 7508709

Regulation of lysyl oxidase mRNA in dermal fibroblasts from normal donors and patients with inherited connective tissue disorders.

H N Yeowell1, M K Marshall, L C Walker, V Ha, S R Pinnell.   

Abstract

Lysyl oxidase (LO) is an extracellular copper-dependent enzyme that catalyzes the initial reaction in the formation of lysine or hydroxylysine-derived crosslinks during collagen biosynthesis. We have isolated a cDNA for human LO from skin fibroblast poly(A+)RNA by PCR using primers based on the recently published sequence of human LO. This cDNA probe detects a major mRNA of 4.2 kb on Northern blots of RNA from normal fibroblasts. The level of LO mRNA was not significantly affected by cell density or by ascorbate treatment. Treatment of skin fibroblasts with hydralazine (50 microM), which increases the mRNAs for both the alpha and the beta subunits of prolyl hydroxylase (PH) and the mRNAs for lysyl hydroxylase, also increased LO mRNA by fourfold over a 72-h time course. In contrast, hydralazine dramatically decreased the mRNAs for alpha 1(I) collagen. Administration of minoxidil (500 microM), which specifically decreases LH activity without affecting PH activity or collagen biosynthesis in skin fibroblasts, stimulated the level of LO mRNA. Neither the administration of penicillamine (100 microM), which interferes with collagen cross-linking, nor the administration of beta-aminopropionitrile, which is a strong irreversible inhibitor of LO, to fibroblasts significantly changed the levels of LO mRNA over a 72-h time course. However, bleomycin (0.6 microgram/ml) significantly decreased the 4.2-kb LO mRNA in contrast to the levels of the alpha 1(I) collagen mRNAs, which were unchanged. No significant change was observed in the steady-state levels of LO mRNAs in fibroblasts isolated from patients with certain connective tissue disorders, including Marfan syndrome, Menkes disease, cutis laxa, and pseudoxanthoma elasticum.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508709     DOI: 10.1006/abbi.1994.1042

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

1.  Lysyl oxidase deficiency: a new cause of human arterial dissection.

Authors:  I Sibon; P Sommer; J M Daniel Lamaziere; J Bonnet
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

Review 2.  Lysyl oxidase: a potential target for cancer therapy.

Authors:  V M Berlin Grace; C Guruvayoorappan
Journal:  Inflammopharmacology       Date:  2010-11-24       Impact factor: 4.473

Review 3.  Keloids: Current and emerging therapies.

Authors:  Nkemcho Ojeh; Ambadasu Bharatha; Uma Gaur; Andrew LeRoy Forde
Journal:  Scars Burn Heal       Date:  2020-08-10

4.  Results of a combination of bleomycin and triamcinolone acetonide in the treatment of keloids and hypertrophic scars.

Authors:  Francisco Miguel Camacho-Martínez; Elena Rodríguez Rey; Francisco Camacho Serrano; Adriana Wagner
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

Review 5.  Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids.

Authors:  Ho Jun Lee; Yong Ju Jang
Journal:  Int J Mol Sci       Date:  2018-03-02       Impact factor: 5.923

Review 6.  The Use of Chemotherapeutics for the Treatment of Keloid Scars.

Authors:  Christopher David Jones; Luke Guiot; Mike Samy; Mark Gorman; Hamid Tehrani
Journal:  Dermatol Reports       Date:  2015-05-21

Review 7.  Nutraceuticals: A Review.

Authors:  Skylar A Souyoul; Katharine P Saussy; Mary P Lupo
Journal:  Dermatol Ther (Heidelb)       Date:  2018-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.